Although focusing on CD8+ and CD3+ cells in the context of IO (immune-oncology) therapy seems logical and useful, it is well known that the immune contexture of a tumor comprises many other cell types beyond CD8+ and CD3+ populations, which have potential prognostic and even predictive relevance too [5]. The gene discussed is CD8A; the disease is neoplasm.